InvestorsHub Logo
Followers 825
Posts 119411
Boards Moderated 16
Alias Born 09/05/2002

Re: DewDiligence post# 7334

Monday, 10/24/2016 12:11:45 PM

Monday, October 24, 2016 12:11:45 PM

Post# of 108191
MAA for AXAL not yet submitted; from today’s PR (#msg-125998500):

We believe that a more than 50 percent increase in 12-month overall survival rate is clinically meaningful, and Advaxis plans to pursue registrational opportunities in Europe in 2017.

This is consistent with what I previously posted—i.e. that ADXS has not yet submitted an MAA for AXAL.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News